Press Release: Dupixent® (Dupilumab) Late-Breaking Phase 3 Data Presented At UEG Week 2022 Showed Significant Histological Remission Of Eosinophilic Esophagitis (Eoe) In Children 1 To 11 Years Old

Media coverage

• Title	Press Release: Dupixent® (Dupilumab) Late-Breaking Phase 3 Data Presented At UEG Week 2022 Showed Significant Histological Remission Of Eosinophilic Esophagitis (Eoe) In Children 1 To 11 Years Old
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	11/10/22
  Persons	Mirna Chehade

• Title	Dupixent® (Dupilumab) Late-Breaking Phase 3 Data Presented At UEG Week 2022 Showed Significant Histological Remission Of Eosinophilic Esophagitis (Eoe) In Children 1 To 11 Years Old'
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	11/10/22
  Persons	Mirna Chehade